Patents by Inventor Lawrence A. Quilliam

Lawrence A. Quilliam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6703482
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from three phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins of SH3 domains and glutathione S-transferase (GST). Preferred peptides are disclosed having a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: March 9, 2004
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Brian K. Kay, Andrew B. Sparks, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der
  • Publication number: 20030186863
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins comprising SH3 and glutathione S-transferase (GST). Preferred peptides are disclosed which comprise a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Application
    Filed: May 31, 2002
    Publication date: October 2, 2003
    Inventors: Andrew B. Sparks, Brian K. Kay, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der, Dana M. Fowlkes, James E. Rider
  • Patent number: 6432920
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins having an SH3 domain and glutathione S-transferase (GST). Preferred peptides are disclosed which comprise a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: August 13, 2002
    Assignees: Cytogen Corporation, University of North Carolina at Chapel Hill
    Inventors: Andrew B. Sparks, Brian K. Kay, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der, Dana M Fowlkes, James E Rider
  • Publication number: 20020091085
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from three phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins comprising SH3 and glutathione S-transferase (GST). Preferred peptides are disclosed which comprise a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Application
    Filed: August 23, 2001
    Publication date: July 11, 2002
    Inventors: Brian K. Kay, Andrew B. Sparks, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der
  • Patent number: 6303574
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from three phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins of SH3 domains and glutathione S-transferase (GST). Preferred peptides are disclosed having a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: October 16, 2001
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Brian K. Kay, Andrew B. Sparks, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der
  • Patent number: 6184205
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins having an SH3 domain and glutathione S-transferase (GST). Preferred peptides are disclosed which comprise a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Grant
    Filed: February 16, 1996
    Date of Patent: February 6, 2001
    Assignees: University of North Carolina at Chapel Hill, Cytogen Corp.
    Inventors: Andrew B. Sparks, Brian K. Kay, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der, Dana M. Fowlkes, James E. Rider